Adam Goulburn invests across biology, healthcare and computing as a founder and managing partner of Dimension. He previously invested at Lux Capital, founded and incubated biotechnology companies including Kallyope, and researched neuroscience at Weill Cornell.
Adam Goulburn invests across biology, healthcare and computing as a founder and managing partner of Dimension. He previously invested at Lux Capital, founded and incubated biotechnology companies including Kallyope, and researched neuroscience at Weill Cornell.
Career
Adam Goulburn holds a PhD (2010) from Monash University and a Bachelor of Commerce / Bachelor of Science (2005) from University of New South Wales.
Founder and Managing Partner at Dimension from 2022-03 to PresentS3Independent Director at Science 37 from 2021 to 2022-09Served on the listed company’s board and nominating and corporate governance committee.
VBFounding CEO at VNV Bio (now Aera Therapeutics) from 2018 to 2021Helped establish the biotechnology company that later became part of Aera Therapeutics.
KFounding CEO at Kallyope from 2014 to 2015Helped establish a biotechnology company studying the gut-brain axis.
WCPostdoctoral Fellow, Neuroscience at Weill Cornell Medical College from 2010 to 2011Researched regenerative stem-cell medicine and brain disorders.
Investing Announcements
Cosigns Received
Jacob KimmelCo-founder & CEO at NewLimit developing epigenetic reprogramming therapeutics for aging and age-related disease.
we’ve been privileged to work with them @newlimit